National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

Bill 117 HR 4369, also known as the National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021, aims to establish centers of excellence in advanced and continuous pharmaceutical manufacturing within the United States. The bill seeks to promote research, development, and education in the field of pharmaceutical manufacturing, with a focus on continuous manufacturing processes.

The centers of excellence established under this bill will be tasked with conducting research and development activities to advance the field of pharmaceutical manufacturing, as well as providing training and education to students and professionals in the industry. The goal is to improve the efficiency, quality, and safety of pharmaceutical manufacturing processes, ultimately leading to better and more affordable medications for patients.

The bill also includes provisions for collaboration between the centers of excellence and other stakeholders in the pharmaceutical industry, including government agencies, academic institutions, and private sector companies. This collaboration is intended to foster innovation and knowledge sharing in the field of pharmaceutical manufacturing. Overall, the National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021 aims to support the growth and advancement of the pharmaceutical manufacturing industry in the United States, ultimately benefiting patients by improving the quality and accessibility of medications.